Ocular FIP treatment gains clearer clinical direction

CURRENT FULL VERSION: Ocular feline infectious peritonitis is moving from a once-dire prognosis to a more protocol-driven treatment category, with new data helping clinicians think more clearly about what happens in the eye during antiviral therapy. The most relevant recent evidence is an observational case series reporting that 20 of 61 cats with FIP, or 33%, had ocular involvement, most commonly as panuveitis, and that 82% of cats with follow-up ophthalmic exams had resolution of uveitis after treatment with remdesivir, GS-441524, or a combination of the two. Overall survival in the ocular cohort was 80%. (pmc.ncbi.nlm.nih.gov)

That matters because ocular FIP has historically been one of the more frustrating presentations to manage. VetGirl’s recent review of the same case series underscores how these cats may first present with vision changes or ocular inflammation before the broader systemic picture is fully clear. Eye lesions can include anterior or posterior uveitis, keratic precipitates, iris color change, dyschoria or anisocoria, hyphema, hypopyon, fibrinous exudate, retinal hemorrhage, vascular tortuosity, and retinal detachment, and they may be unilateral or bilateral. In some cats, ocular signs are the dominant presentation. Older supportive care approaches did little to change the underlying disease course, but antivirals have changed that conversation substantially. (pmc.ncbi.nlm.nih.gov)

The case series adds practical detail. All cats were started on an 84-day treatment course, and 85% initially received remdesivir. Among those, 70% received higher-dose therapy in the 15 to 20 mg/kg/day range. The authors noted that ocular disease occurred in both effusive and non-effusive FIP, was bilateral in 70% of affected cats, and was usually linked to uveitis. Most cats with anterior uveitis also received topical anti-inflammatory medication, suggesting that antiviral treatment and local eye-directed therapy were used together in real-world management. (pmc.ncbi.nlm.nih.gov)

Those findings fit with broader FIP treatment literature. A Journal of Veterinary Internal Medicine study on combination remdesivir and oral GS-441524 reported that neurologic and ocular cases were started at 15 to 20 mg/kg every 24 hours because of limited drug access across the blood-ocular and blood-brain barriers. Clinician-facing expert guidance has echoed that point, noting that cats with ocular and neurologic FIP appear to require larger doses as inflammation evolves and those barriers change during treatment. VetGirl’s recent discussion of dosing and duration adjustments also frames the same issue in practical terms: cats often improve clinically within the first week, but that early response does not necessarily mean viral clearance, especially in harder-to-penetrate tissues like the eye and CNS. That is one reason clinicians are paying closer attention to whether higher induction dosing and more objective treatment-stop criteria may help refine care beyond the traditional fixed 12-week course. (academic.oup.com)

The regulatory backdrop is also important. In the U.S., compounded oral GS-441524 became available on June 1, 2024, through Stokes Pharmacy in collaboration with Bova, according to Cornell’s Feline Health Center. FDA’s Center for Veterinary Medicine has separately said it does not intend to enforce animal drug approval requirements for compounded GS-441524 when it is prescribed by a veterinarian for a specific cat patient with FIP under the conditions in Guidance for Industry #256. That hasn’t made the product FDA-approved, but it has given veterinarians a more workable and transparent route to access treatment. (vet.cornell.edu)

Industry and expert commentary reflects that transition. Clinician’s Brief described the earlier ethical bind created when pet parents turned to internet-sourced, unlicensed formulations because legal veterinary access was limited. More recent guidance from the ABCD notes growing evidence that some FIP cases may respond to shorter treatment durations than the traditional 12 weeks, although that evidence is still emerging and included only a very small number of ocular cases in the cited trial. VetGirl’s broader FIP clinical update adds useful context here too: response rates with antiviral therapy are now commonly discussed in the roughly 85% to 90% range overall, but diagnosis and treatment planning still depend heavily on pattern recognition, risk factors, and presumptive clinical decision-making in practice. In other words, the field is becoming more evidence-based, but ocular FIP still sits in a subgroup where many decisions remain experience-driven. (cliniciansbrief.com)

Why it matters: For veterinarians, the key takeaway is that ocular FIP should no longer be viewed as an automatic therapeutic dead end, but it also shouldn’t be managed as a standard FIP case without attention to dose intensity, route, ophthalmic findings, and follow-up. The available evidence supports meaningful response rates, especially for uveitis, yet it also underscores the need for careful client counseling about treatment length, adjunctive eye medications, relapse risk, and the limits of current data. For general practitioners, earlier recognition of ocular signs may now meaningfully change outcomes, particularly when referral, imaging, or ophthalmic consultation can help define the extent of disease. And because definitive diagnosis remains difficult in many real-world cases, clinicians still need to integrate signalment, systemic findings, ocular exam results, and treatment response into a practical presumptive approach. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely center on prospective data that sort out the best dose, duration, and sequencing of remdesivir and GS-441524 for ocular-only disease, as well as whether shorter-course protocols can safely be extended to these more complex presentations. Another closely watched question is how objective monitoring tools, including trends in acute phase proteins and albumin:globulin ratio discussed in recent VetGirl coverage, may help clinicians decide when treatment can safely be stopped rather than relying on clinical improvement alone. (abcdcatsvets.org)